Japan’s daily coronavirus cases (Covid-19) have exceeded 3,000 for the first time while the government delays stricter measures for fear of hurting the economy ahead of the holiday season.
The 3,030 new Covid-19 cases, including 621 in Tokyo, took Japan’s national tally to 1,77,287 with 2,562 deaths, the health ministry said on Sunday.
Experts say serious Covid-19 cases are on the rise around the country, putting the burden on hospitals and affecting the daily medical treatment for other patients. They urged authorities to take measures such as suspending out-of-town trips and requesting stores to close early.
Recent media surveys show support ratings for the government of Prime Minister Yoshihide Suga have dropped about 20 points from around 70% during his first three months in office amid public discontent over his Covid-19 handling.
Japan issued a non-binding state of emergency in the spring and has survived earlier infection peaks without a lockdown. Experts say the ongoing resurgence in the dry and cold season would be a bigger challenge.
South Korea has set another record for its daily coronavirus tally with 1,030, as authorities struggle to suppress the viral spread. The Korea disease control and prevention agency said today that the additional cases including two deaths had raised the national caseload to 42,766 with 580 fatalities.
Ironically, the densely populated Seoul area — where authorities have shut nightclubs and other high-risk venues, banned late-night dining and taken other steps to slow the spread — are reporting about 80% of the new cases. The stringent measures have shown little effect.
Prime Minister Chung Sye-kyun said yesterday his government may have to enforce its highest-level social distancing rules if the virus does not slow down.
Such restrictions would ban a gathering of more than 10 people, shut down schools, theatres and department stores and suspend professional sports leagues.
South Korea has arranged to buy 20 million doses of the vaccine developed by Pfizer and its German partner BioNTech. The country also has deals for 20 million doses each for the vaccines developed by Moderna Inc and AstraZeneca Plc/Oxford University and for another 4 million doses from Johnson & Johnson.